vs
Royalty Pharma plc（RPRX）与Sarepta Therapeutics, Inc.（SRPT）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Sarepta Therapeutics, Inc.的1.7倍（$622.0M vs $369.6M），Royalty Pharma plc净利率更高（34.4% vs -111.5%，领先146.0%），Royalty Pharma plc同比增速更快（4.8% vs -42.1%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 1.4%）
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
Sarepta Therapeutics是一家总部位于美国马萨诸塞州剑桥的生物医药企业，专注于医学研究与药物研发。公司成立于1980年，前身为AntiVirals，后续先后更名为AVI BioPharma及现名，截至2023年已有四款获批上市药物，在相关疾病治疗领域深耕技术创新。
RPRX vs SRPT — 直观对比
营收规模更大
RPRX
是对方的1.7倍
$369.6M
营收增速更快
RPRX
高出46.9%
-42.1%
净利率更高
RPRX
高出146.0%
-111.5%
两年增速更快
RPRX
近两年复合增速
1.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $622.0M | $369.6M |
| 净利润 | $214.2M | $-412.2M |
| 毛利率 | — | — |
| 营业利润率 | 62.4% | -111.4% |
| 净利率 | 34.4% | -111.5% |
| 营收同比 | 4.8% | -42.1% |
| 净利润同比 | 2.9% | -359.2% |
| 每股收益（稀释后） | $0.49 | $-3.92 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RPRXSRPT
| Q4 25 | $622.0M | $369.6M | ||
| Q3 25 | $609.3M | $370.0M | ||
| Q2 25 | $578.7M | $513.1M | ||
| Q1 25 | $568.2M | $611.5M | ||
| Q4 24 | $593.6M | $638.2M | ||
| Q3 24 | $564.7M | $429.8M | ||
| Q2 24 | $537.3M | $360.5M | ||
| Q1 24 | $568.0M | $359.5M |
净利润RPRXSRPT
| Q4 25 | $214.2M | $-412.2M | ||
| Q3 25 | $288.2M | $-50.6M | ||
| Q2 25 | $30.2M | $196.9M | ||
| Q1 25 | $238.3M | $-447.5M | ||
| Q4 24 | $208.2M | $159.0M | ||
| Q3 24 | $544.0M | $33.6M | ||
| Q2 24 | $102.0M | $6.5M | ||
| Q1 24 | $4.8M | $36.1M |
毛利率RPRXSRPT
| Q4 25 | — | — | ||
| Q3 25 | — | 59.3% | ||
| Q2 25 | — | 70.3% | ||
| Q1 25 | — | 77.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 78.7% | ||
| Q2 24 | — | 87.6% | ||
| Q1 24 | — | 85.9% |
营业利润率RPRXSRPT
| Q4 25 | 62.4% | -111.4% | ||
| Q3 25 | 70.1% | -27.9% | ||
| Q2 25 | 36.3% | 22.5% | ||
| Q1 25 | 94.0% | -49.1% | ||
| Q4 24 | 60.9% | 25.3% | ||
| Q3 24 | — | 5.2% | ||
| Q2 24 | 50.2% | -0.2% | ||
| Q1 24 | -13.0% | 9.7% |
净利率RPRXSRPT
| Q4 25 | 34.4% | -111.5% | ||
| Q3 25 | 47.3% | -13.7% | ||
| Q2 25 | 5.2% | 38.4% | ||
| Q1 25 | 41.9% | -73.2% | ||
| Q4 24 | 35.1% | 24.9% | ||
| Q3 24 | 96.3% | 7.8% | ||
| Q2 24 | 19.0% | 1.8% | ||
| Q1 24 | 0.8% | 10.0% |
每股收益（稀释后）RPRXSRPT
| Q4 25 | $0.49 | $-3.92 | ||
| Q3 25 | $0.67 | $-0.50 | ||
| Q2 25 | $0.07 | $1.89 | ||
| Q1 25 | $0.55 | $-4.60 | ||
| Q4 24 | $0.46 | $1.56 | ||
| Q3 24 | $1.21 | $0.34 | ||
| Q2 24 | $0.23 | $0.07 | ||
| Q1 24 | $0.01 | $0.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $618.7M | $939.6M |
| 总债务越低越好 | $9.0B | $829.0M |
| 股东权益账面价值 | $9.7B | $1.1B |
| 总资产 | $19.6B | $3.3B |
| 负债/权益比越低杠杆越低 | 0.92× | 0.73× |
8季度趋势，按日历期对齐
现金及短期投资RPRXSRPT
| Q4 25 | $618.7M | $939.6M | ||
| Q3 25 | $938.9M | $851.0M | ||
| Q2 25 | $631.9M | $800.1M | ||
| Q1 25 | $1.1B | $522.8M | ||
| Q4 24 | $929.0M | $1.4B | ||
| Q3 24 | $950.1M | $1.2B | ||
| Q2 24 | $1.8B | $1.5B | ||
| Q1 24 | $843.0M | $1.4B |
总债务RPRXSRPT
| Q4 25 | $9.0B | $829.0M | ||
| Q3 25 | $8.9B | $140.5M | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.6B | $1.1B | ||
| Q3 24 | $7.6B | $1.2B | ||
| Q2 24 | $7.6B | $1.2B | ||
| Q1 24 | $6.1B | $1.2B |
股东权益RPRXSRPT
| Q4 25 | $9.7B | $1.1B | ||
| Q3 25 | $9.6B | $1.3B | ||
| Q2 25 | $9.5B | $1.4B | ||
| Q1 25 | $9.8B | $1.1B | ||
| Q4 24 | $10.3B | $1.5B | ||
| Q3 24 | $10.3B | $1.2B | ||
| Q2 24 | $9.8B | $1.1B | ||
| Q1 24 | $9.9B | $961.2M |
总资产RPRXSRPT
| Q4 25 | $19.6B | $3.3B | ||
| Q3 25 | $19.3B | $3.5B | ||
| Q2 25 | $18.3B | $3.7B | ||
| Q1 25 | $17.6B | $3.5B | ||
| Q4 24 | $18.2B | $4.0B | ||
| Q3 24 | $18.0B | $3.6B | ||
| Q2 24 | $17.7B | $3.4B | ||
| Q1 24 | $16.1B | $3.2B |
负债/权益比RPRXSRPT
| Q4 25 | 0.92× | 0.73× | ||
| Q3 25 | 0.93× | 0.11× | ||
| Q2 25 | 0.84× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.74× | 0.74× | ||
| Q3 24 | 0.74× | 1.01× | ||
| Q2 24 | 0.78× | 1.14× | ||
| Q1 24 | 0.62× | 1.29× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $827.1M | $131.2M |
| 自由现金流经营现金流 - 资本支出 | — | $127.6M |
| 自由现金流率自由现金流/营收 | — | 34.5% |
| 资本支出强度资本支出/营收 | — | 1.0% |
| 现金转化率经营现金流/净利润 | 3.86× | — |
| 过去12个月自由现金流最近4个季度 | — | $-307.5M |
8季度趋势，按日历期对齐
经营现金流RPRXSRPT
| Q4 25 | $827.1M | $131.2M | ||
| Q3 25 | $702.6M | $-14.6M | ||
| Q2 25 | $364.0M | $261.3M | ||
| Q1 25 | $596.1M | $-583.4M | ||
| Q4 24 | $742.5M | $92.0M | ||
| Q3 24 | $703.6M | $-70.7M | ||
| Q2 24 | $658.2M | $14.9M | ||
| Q1 24 | $664.6M | $-242.1M |
自由现金流RPRXSRPT
| Q4 25 | — | $127.6M | ||
| Q3 25 | — | $-37.5M | ||
| Q2 25 | — | $229.5M | ||
| Q1 25 | — | $-627.1M | ||
| Q4 24 | — | $54.0M | ||
| Q3 24 | — | $-108.0M | ||
| Q2 24 | — | $-14.2M | ||
| Q1 24 | — | $-274.5M |
自由现金流率RPRXSRPT
| Q4 25 | — | 34.5% | ||
| Q3 25 | — | -10.1% | ||
| Q2 25 | — | 44.7% | ||
| Q1 25 | — | -102.5% | ||
| Q4 24 | — | 8.5% | ||
| Q3 24 | — | -25.1% | ||
| Q2 24 | — | -3.9% | ||
| Q1 24 | — | -76.4% |
资本支出强度RPRXSRPT
| Q4 25 | — | 1.0% | ||
| Q3 25 | — | 6.2% | ||
| Q2 25 | — | 6.2% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | — | 6.0% | ||
| Q3 24 | — | 8.7% | ||
| Q2 24 | — | 8.1% | ||
| Q1 24 | — | 9.0% |
现金转化率RPRXSRPT
| Q4 25 | 3.86× | — | ||
| Q3 25 | 2.44× | — | ||
| Q2 25 | 12.06× | 1.33× | ||
| Q1 25 | 2.50× | — | ||
| Q4 24 | 3.57× | 0.58× | ||
| Q3 24 | 1.29× | -2.10× | ||
| Q2 24 | 6.45× | 2.31× | ||
| Q1 24 | 139.10× | -6.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
SRPT
| Pmo Products | $202.5M | 55% |
| Elevidys | $110.4M | 30% |
| Other | $56.7M | 15% |
